Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
64 hedge funds and large institutions have $53.5M invested in Infinity Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 16 closing their positions.
384% more call options, than puts
Call options by funds: $654K | Put options by funds: $135K
0% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 15
3% less funds holding
Funds holding: 66 → 64 (-2)
10% less capital invested
Capital invested by funds: $59.6M → $53.5M (-$6.05M)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$11M |
| 2 |
First Eagle Investment Management
New York
|
+$1.01M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$832K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$400K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$393K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.54M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$3.67M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$837K |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$747K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$585K |
INFI Hedge Fund Activity: Q2 2018 in Review
64 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q2 2018, worth a combined $53.5M — down 10% from $59.6M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of INFI and 14 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 15 added.
The largest buyer was BVF Inc, adding an estimated $11M. The largest seller was Fidelity Investments, exiting entirely with an estimated $7.54M sold.
- 64 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q2 2018, down from 66 in Q1 2018.
- Funds reported $53.5M of Infinity Pharmaceuticals, Inc. stock for Q2 2018, down 10% quarter-over-quarter.
- 14 funds opened new Infinity Pharmaceuticals, Inc. positions in Q2 2018 and 16 closed out, a net change of -2 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q2 2018 was BVF Inc, an estimated $11M added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q2 2018 was Fidelity Investments, an estimated $7.54M sold.
Based on aggregated 13F filings for Q2 2018.